2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab

Nandita Nadig; Adarsh Bhimraj; Kelly Cawcutt; Kathleen Chiotos; Amy L Dzierba; Arthur Y Kim; Greg S Martin; Jeffrey C Pearson; Amy Hirsch Shumaker; Lindsey R Baden; Roger Bedimo; Vincent Chi-Chung Cheng; Kara W Chew; Eric S Daar; David V Glidden; Erica J Hardy; Steven Johnson; Jonathan Z Li; Christine MacBrayne; Mari M Nakamura; Laura Riley; Robert W Shafer; Shmuel Shoham; Pablo Tebas; Phyllis C Tien; Jennifer Loveless; Yngve Falck-Ytter; Rebecca L Morgan; Rajesh T Gandhi

doi:10.1093/cid/ciaf235

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab

Clin Infect Dis. 2025 May 22:ciaf235. doi: 10.1093/cid/ciaf235. Online ahead of print.

Authors

Nandita Nadig¹, Adarsh Bhimraj², Kelly Cawcutt³, Kathleen Chiotos⁴, Amy L Dzierba⁵, Arthur Y Kim^{6

7}, Greg S Martin⁸, Jeffrey C Pearson⁹, Amy Hirsch Shumaker^{10

11}, Lindsey R Baden^{6

12}, Roger Bedimo¹³, Vincent Chi-Chung Cheng¹⁴, Kara W Chew¹⁵, Eric S Daar¹⁶, David V Glidden¹⁷, Erica J Hardy¹⁸, Steven Johnson¹⁹, Jonathan Z Li^{6

12}, Christine MacBrayne²⁰, Mari M Nakamura^{21

22}, Laura Riley^{23

24}, Robert W Shafer²⁵, Shmuel Shoham²⁶, Pablo Tebas²⁷, Phyllis C Tien²⁸, Jennifer Loveless²⁹, Yngve Falck-Ytter^{10

11}, Rebecca L Morgan^{10

30}, Rajesh T Gandhi^{6

7}

Affiliations

¹ Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
² Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
³ Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
⁴ Department of Anesthesiology and Critical Care, Children's Hospital of Philadelphia/University of Pennsylvania, Philadelphia, Pennsylvania, USA.
⁵ Department of Medicine, New York University Grossman School of Medicine, New York City, New York, USA.
⁶ Harvard Medical School, Boston, Massachusetts, USA.
⁷ Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
⁸ Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, Georgia, USA.
⁹ Department of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts, USA.
¹⁰ Department of Medicine, Case Western Reserve University, School of Medicine, Cleveland, Ohio, USA.
¹¹ Department of Medicine, VA Northeast Ohio Healthcare System, Cleveland, Ohio, USA.
¹² Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
¹³ Department of Medicine, UT Southwestern/VA North Texas Health Care System, Dallas, Texas, USA.
¹⁴ Department of Microbiology, Queen Mary Hospital, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
¹⁵ Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
¹⁶ Department of Medicine, Harbor-UCLA Medical Center, Torrance, California, USA.
¹⁷ Department of Epidemiology and Biostatistics, UCSF, San Francisco, California, USA.
¹⁸ Departments of Medicine and Obstetrics and Gynecology, Brown University, Providence, Rhode Island, USA.
¹⁹ Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
²⁰ Department of Pharmacy, Children's Hospital Colorado, Aurora, Colorado, USA.
²¹ Antimicrobial Stewardship Program and Division of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts, USA.
²² Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
²³ New York-Presbyterian Hospital, New York City, New York, USA.
²⁴ Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York City, New York, USA.
²⁵ Department of Medicine, Stanford University, Palo Alto, California, USA.
²⁶ Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
²⁷ Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
²⁸ Department of Medicine, UCSF/VA San Francisco Health Care System, San Francisco, California, USA.
²⁹ Clinical Affairs and Practice Guidelines, Infectious Diseases Society of America, Arlington, Virginia, USA.
³⁰ Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.

PMID: 40402009
DOI: 10.1093/cid/ciaf235

Abstract

This article provides a focused update to the clinical practice guideline on the treatment and management of patients with COVID-19, developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of vilobelimab in hospitalized adults with critical COVID-19. The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.

Keywords: COVID-19; SARS-CoV-2; guideline; monoclonal antibody; vilobelimab.

© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.